Therapeutic | Efalizumab |
Target | ITGAL |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHPSDSETRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARGIYFYGTTYFDYWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK |
100% seqID Fv Structure | 3eo9 [Fvs: HL], 3eoa [Fvs: BA, HL], 3eob [Fvs: BA, HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 3eo9 [Fvs: HL] |
100% seqID Structure | 3eoa [Fvs: BA, HL] |
100% seqID Structure | 3eob [Fvs: BA, HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (Aug '22) | Approved |
Estimated Status (Aug '22) | NFD |
Recorded Developmental Technology | na |
INN Year Proposed | 2001 |
INN Year Recommended | 2002 |
Companies Involved | Genentech, Merck Serono, XOMA |
Conditions Approved | Psoriasis |
Conditions Active | na |
Conditions Discontinued | Psoriatic arthritis, Type 1 diabetes mellitus |
Notes |
SAbDab papers
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]
Thera-SAbDab paper
Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]